Top Markets
#1 Status Status +17.68%
#2 Hex Trust USD Hex Trust USD +4.50%
#3 Bitway Bitway +4.24%
#4 MANTRA MANTRA +3.79%
#5 龙虾 (Lobster) 龙虾 (Lobster) +3.74%
#6 ThunderCore ThunderCore +3.62%
#7 Civic Civic +2.86%
#8 Infinity Ground Infinity Ground +2.69%
#9 MemeCore MemeCore +2.66%
#10 Electroneum Electroneum +2.59%
Coin of the day
Status Status
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rang în acțiuni #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preț acțiune
$451.59
Capitalizare de piață
$114.70B
Schimbare (1 zi)
-2.36%
Schimbare (1 an)
-11.89%
Țară
US
Tranzacționează Vertex Pharmaceuticals Incorporated (VRTX)

Categorie

Healthcare
Câștiguri pentru Vertex Pharmaceuticals Incorporated (VRTX)
Câștiguri în Dec 2025 TTM: $4.64B
Conform celor mai recente rapoarte financiare ale Vertex Pharmaceuticals Incorporated, câștigurile actuale ale companiei sunt $4.64B. În anul 2024, compania a înregistrat un câștig de $248.50M, o scădere comparativ cu câștigului din 2023, care a fost de $4.38B. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Vertex Pharmaceuticals Incorporated din 2000 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
2026 (TTM) $4.64B 0.00%
2025 $4.64B 1,768.49%
2024 $248.50M -94.33%
2023 $4.38B 3.48%
2022 $4.23B 55.01%
2021 $2.73B -12.40%
2020 $3.12B 123.45%
2019 $1.39B 132.39%
2018 $600.24M -3,925.87%
2017 $-15.69M -76.71%
2016 $-67.37M -87.96%
2015 $-559.58M -23.85%
2014 $-734.88M -24.71%
2013 $-976.12M 7,783.99%
2012 $-12.38M -120.48%
2011 $60.45M -108.01%
2010 $-754.63M 17.51%
2009 $-642.18M 38.35%
2008 $-464.18M 8.73%
2007 $-426.91M 106.35%
2006 $-206.89M 19.32%
2005 $-173.39M 9.39%
2004 $-158.51M -54.37%
2003 $-347.35M 190.28%
2002 $-119.66M 1.50%
2001 $-117.89M 119.92%
2000 $-53.61M 0.00%
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B 340.58%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 12.65%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -53.96%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -65.23%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -68.75%
NL